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Objectives. The purpose of this prospective study was to evalu-
ate the immediate results and the 6-month angiographic recurrent
restenosis rate after balloon angioplasty for in-stent restenosis.
Background. Despite excellent immediate and mid-term re-
sults, 20% to 30% of patients with coronary stent implantation will
present an angiographic restenosis and may require additional
treatment. The optimal treatment for in-stent restenosis is still
unclear.
Methods. Quantitative coronary angiography (QCA) analyses
were performed before and after stent implantation, before and
after balloon angioplasty for in-stent restenosis and on a 6-month
systematic coronary angiogram to assess the recurrent angio-
graphic restenosis rate.
Results. Balloon angioplasty was performed in 52 patients
presenting in-stent restenosis. In-stent restenosis was either dif-
fuse (>2 10 mm) inside the stent (71%) or focal (29%). Mean stent
length was 16 6 7 mm. Balloon diameter of 2.98 6 0.37 mm and
maximal inflation pressure of 10 6 3 atm were used for balloon
angioplasty. Angiographic success rate was 100% without any
complication. Acute gain was lower after balloon angioplasty for
in-stent restenosis than after stent implantation: 1.19 6 0.60 mm
vs. 1.75 6 0.68 mm (p 5 0.0002). At 6-month follow-up, 60% of
patients were asymptomatic and no patient died. Eighteen pa-
tients (35%) had repeat target vessel revascularization. Angio-
graphic restenosis rate was 54%. Recurrent restenosis rate was
higher when in-stent restenosis was diffuse: 63% vs. 31% when
focal, p 5 0.046.
Conclusions. Although balloon angioplasty for in-stent resten-
osis can be safely and successfully performed, it leads to less
immediate stenosis improvement than at time of stent implanta-
tion and carries a high recurrent angiographic restenosis rate at
6 months, in particular in diffuse in-stent restenosis lesions.
(J Am Coll Cardiol 1998;32:980–4)
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Two large prospective randomized studies (1,2) have demon-
strated the superiority of Palmaz–Schatz stents over balloon
angioplasty on restenosis rate in patients presenting with stable
angina and de novo lesions on arteries larger than 3 mm. With
the use of high delivery pressures (3) and antiplatelet regimen
(4–6), the incidence of acute stent thrombosis and vascular
complications rate has dramatically decreased, explaining the
success of stent and its wide utilization across the world.
However, despite excellent immediate results, 20% to 30% of
patients may present with an angiographic restenosis and may
require additional treatment. Balloon angioplasty for in-stent
restenosis has been performed with excellent immediate re-
sults (7–16) but angiographic restenosis rate seems to be high.
In the few retrospective studies (7–9), which reported incom-
plete 6-month angiographic follow-up, restenosis rate varied
between 30% and 57%. Recently, Bauters et al. (16) reported
a 22% angiographic restenosis rate after successful repeat
intervention in a series of 103 patients. Rotational atherectomy
(17) or laser angioplasty (18,19) could be more effective in
treating in-stent restenosis, however no data are yet available
on angiographic restenosis rate following these procedures.
The aim of this prospective study was to evaluate the
immediate results and 6-month angiographic recurrent resten-
osis rate after balloon angioplasty for in-stent restenosis by
performing a systematic coronary angiography at 6 months in
all patients.
Methods
Patient selection. Our study group included 52 consecutive
patients and 57 stents presenting with angiographic in-stent
restenosis on a coronary angiogram performed between Janu-
ary 1995 and December 1996. Coronary angiogram was per-
formed 6 6 8 months (2 to 59 months) after stent implantation
for recurrence of symptoms and/or positive stress test. Imme-
diate results were assessed and a systematic coronary angio-
gram was scheduled at 6 months for each patient to assess
recurrent restenosis rate, or earlier if clinical suspicion of
restenosis.
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Definitions. Angina was classified according to the Cana-
dian Cardiac Society angina classification (20). Myocardial
infarction was defined by two of the following: chest pain
lasting .30 min, new Q waves or ST segment elevation
(.1 mV) in at least two contiguous leads on the 12-lead
electrocardiogram (ECG), or a more than twofold increase in
creatine kinase (CK)-MB above baseline to an abnormal level.
Lesion morphology before stent implantation was classified
according to the American College of Cardiology/American
Heart Association (ACC/AHA) classification (21).
Balloon angioplasty procedure for in-stent restenosis. Bal-
loon size used for balloon angioplasty was determined to
obtain a reference artery diameter: balloon diameter ratio
close to 1. During the procedure, patients received an intra-
coronary bolus injection of heparin (5,000 to 7,500 U). The
arterial sheath was removed 4 h after the end of the procedure.
Patients were receiving aspirin (250 mg daily). No ticlopidin or
reopro were administered to the patients.
Angiographic analysis. Quantitative coronary angio-
graphic analyses were performed: 1) before and after balloon
angioplasty for in-stent restenosis; 2) at 6-month follow-up to
assess recurrent restenosis rate. They were compared with the
angiographic analyses performed before and after stent im-
plantation. At least two angiographic projections (orthogonal
if possible) were recorded in such a way that they were suitable
for quantitative analysis by the Philips DCI automated QCA
system. The absolute stenosis minimal lumen diameter (MLD)
and reference diameter were measured on-line by the com-
puter using the known contrast-empty guiding catheter as a
scaling device after intracoronary injection of 150 mg of
nitroglycerin. Acute gain was defined as the difference between
the MLD immediately after the procedure (stent implantation
or balloon angioplasty) and the MLD before the procedure.
Angiographically visible dissections were defined according to
the modified National Heart, Lung and Blood Institute criteria
(22). Angiographic success was defined as a residual diameter
stenosis #50% in the absence of severe coronary artery
dissection (type D1 or greater). Clinical success was defined as
an angiographic success in the absence of major complications
such as death, myocardial infarction and bypass surgery (23).
Angiographic restenosis was defined by a diameter stenosis
$50%.
Follow-up. In-hospital, ECG was performed immediately
and 12 h after balloon angioplasty. Creatine kinase measure-
ments were performed on the following day after angioplasty.
Complications and clinical events were noted, including death,
need for coronary bypass surgery or repeat coronary angio-
plasty, myocardial infarction and vascular complications. All
patients were asked to return for a 6-month follow-up angio-
gram, regardless of symptomatic status; angiography was per-
formed earlier if there was a clinical indication. The following
information was obtained: Canadian class angina, need for
rehospitalization, cardiac events such as myocardial infarction,
coronary artery bypass surgery or death. If the patient did not
return for 6-month angiogram, clinical information was ob-
tained by phone.
Statistical analysis. For the five patients who had more
than one stent presenting in-stent restenosis, we selected one
stent from each patient using a random unit generator and
deleted the other stent from the formal analyses. Thus, all
formal analyses were performed on 52 patients. Data were
reported as mean 6 SD values. Comparisons were made using
Student’s t-test for continuous variables and chi-square test for
qualitative clinical variables; p , 0.05 was considered signifi-
cant.
Results
Study group. The clinical characteristics of our population
are presented in Table 1. Baseline angiographic characteristics
obtained before stent implantation are shown in Table 2. Mean
ejection fraction was 64% 6 10%. Mean lesion length was
14 6 5 mm.
Stent implantation. Maximal balloon pressure used for
stent deployment was 11 6 3 atm and maximal balloon
diameter was 3.05 6 0.28 mm. The indications for stent
implantation were: suboptimal result in 7, de novo lesion in 23,
Abbreviations and Acronyms
CK 5 creatine kinase
ECG 5 electrocardiogram
QCA 5 quantitative coronary analysis
MLD 5 minimal lumen diameter
Table 1. Clinical Characteristics of the 52 Patients
N %





Unstable angina 18 35
Prior myocardial infarction 17 33
Prior bypass surgery 3 6
Data presented are mean value 6 SD or number (%) of patients.
Table 2. Angiographic and Procedural Characteristics
N %
Target vessel
Left anterior descending 28 54
Left circumflex 8 15
Right coronary artery 14 27
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occlusive or nonocclusive dissection in 16, restenosis in 6. In
63% of cases, Palmaz–Schatz stents were implanted, Freedom
stents in 17% and Advanced Vascular Engineering (AVE) in
13%. The remaining 7% were stents of various designs. Mean
stent length was 16 6 7 mm (6 to 40 mm).
In-stent restenosis characteristics. In-stent restenosis was
either diffuse ($10 mm; 71%) or focal (29%). When focal,
in-stent restenosis was located either inside the stent (n 5 11;
21%) or at one of the extremities of the stent (n 5 4; 8%).
Mean in-stent restenosis length was 16 6 8 mm (5.5 to 38 mm).
Balloon angioplasty procedure for in-stent restenosis. Bal-
loon angioplasty was performed at a mean of 5.9 6 8.2 months
after stent implantation (2 to 59). Indications for repeat
intervention were the presence of angina or stress test isch-
emia, or both in all the patients. Maximal balloon diameter
used for balloon angioplasty was 2.98 6 0.37 mm, and maximal
balloon inflation pressure was 10 6 3 atm, two parameters not
statistically different from those used for stent implantation.
After balloon angioplasty, there was no angiographic evidence
of dissection or thrombus. Angiographic success rate was
100%.
Immediate and in-hospital clinical outcome. No patient
died, developed myocardial infarction or required emergency
coronary artery bypass graft surgery. There was no case of
abrupt vessel closure after dilatation. Bleeding and vascular
complications were not observed.
Clinical follow-up at 6 months. Clinical follow-up was
obtained in all patients at a mean of 5.3 6 3.5 months. A
majority of patients (60%) was asymptomatic. There was no
death and no patient developed myocardial infarction. Target
vessel revascularization was performed in 18 (35%) patients:
coronary bypass surgery in nine and repeat balloon angioplasty
in nine patients with stent implantation inside the first one in
five cases. All these procedures were uneventful.
Angiographic follow-up. Follow-up coronary angiogram
was obtained in 48 patients (i.e., in 92% of patients and stents
suitable for follow-up). Mean follow-up period was 5.7 6 3.6
months. Indications for repeat angiogram were: clinical and/or
stress test suspicion of restenosis in 19 patients and systematic
control in 29 patients. Recurrent restenosis was observed in 26
of 48 stents, which was a 54% angiographic restenosis rate.
Four patients did not return for control angiogram: all of them
were asymptomatic at 6 months.
Quantitative angiographic analysis. All the measurements
obtained at the time of stent implantation, at the time of
balloon angioplasty for in-stent restenosis and at 6-month
follow-up angiogram were compared and are shown on Table
3. Acute gain was less after balloon angioplasty for in-stent
restenosis than after stent implantation: 1.19 6 0.60 mm vs.
1.75 6 0.68 mm (p 5 0.0002).
Angiographic pattern of in-stent restenosis and its relation
with recurrent restenosis. Diffuse pattern was far more fre-
quent than focal pattern: 71% vs. 29%. Using univariate
analysis, the diffuse pattern of in-stent restenosis was the only
predictor of recurrent restenosis after balloon angioplasty for
in-stent restenosis (p 5 0.046). Recurrent restenosis rate was
63% vs. 31% when in-stent restenosis was focal (p 5 0.046).
Similarly, target vessel revascularization was required more
often when in-stent restenosis was diffuse: 49% vs. 8%, p 5
0.009. Interestingly, the morphology of the recurrent restenotic
lesion at 6 months was comparable to that observed initially at
the time of in-stent restenosis in 76% of cases.
Discussion
During the past few years there has been a dramatic
explosion in coronary stent utilization. There is a general
recognition that stents address many of the major limitations
of conventional balloon angioplasty, offering a solution for
abrupt or threatened closure, a safer and more effective
therapy for patients with saphenous vein graft disease and a
partial solution to the problem of restenosis (1,2). Further-
more, stent implantation techniques have been revised (3) and
pharmacologic regimens (4–6) have been improved, both
leading to a decrease in the frequency of stent thrombosis with
fewer bleeding/vascular complications and a shorter hospital
stay. However, 20% to 30% of patients will present restenosis
(1,2) and may require further management. Few data are yet
available on the best choice of revascularization treatment in
these patients. Balloon angioplasty for in-stent restenosis has
been evaluated in few retrospective studies (7–15) with excel-
lent immediate results. Macander et al. (9) reported a high
success rate of 97% in 75 restenotic Cook (Gianturco–Roubin)
stents. Success rate was 100% and 97.6% respectively in two
recent series of balloon angioplasty for in-stent restenosis
(13,14). Clinical follow-up obtained in several series (14,15)
Table 3. Angiographic Analysis
Stent Implantation BA for ISR
6-month
Follow-upPre Post Pre Post
Mean reference diameter (mm) 2.95 6 0.47 3.24 6 0.45† 2.91 6 0.55* 3.00 6 0.60** 2.97 6 0.67
Minimal lumen diameter (mm) 0.89 6 0.51 2.65 6 0.44 1.02 6 0.47 2.21 6 0.54*** 1.48 6 0.68
Diameter stenosis (%) 73 6 15 18 6 10 66 6 11 25 6 12 48 6 23
*p 5 0.012 reference diameter pre-BA vs. reference diameter poststent; **p 5 0.02 reference diameter post-BA vs.
reference diameter poststent; ***p 5 0.0001 MLD post-BA vs. MLD poststent; †p , 0.0001 reference diameter prestent
vs. reference diameter poststent. Data presented are mean value 6 SD. BA 5 balloon angioplasty; ISR 5 in-stent
restenosis; MLD 5 minimal lumen diameter.
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appears satisfactory with a 18% to 36% need for repeat target
vessel revascularization. Recently, Reimers et al. (15) reported
complete clinical follow-up on 124 patients with a target vessel
revascularization rate of 11%. However, angiographic mid-
term results appear less encouraging, with high restenosis rate
reaching 57% in the few retrospective studies (7–9) reporting
incomplete angiographic follow-up on less than 50% of pa-
tients.
Thus, the aim of our prospective study was to evaluate the
immediate results and the angiographic recurrent restenosis
rate observed after balloon angioplasty for in-stent restenosis
by performing a systematic coronary angiogram at 6 months. In
our series, angiographic follow-up was obtained in 93% of
patients.
Results of our series. In our prospective series of 52
patients presenting with in-stent restenosis and treated by
balloon angioplasty, immediate results were excellent with a
100% clinical and angiographic success rate. There was no
major complication. These optimal results are in agreement
with those reported in previous series (13,14,16), reporting
excellent immediate results and the absence of major compli-
cations. This common observation may result from the mech-
anism of balloon angioplasty which is somewhat different.
Applying pressure in a stented wall does not create disruption
as compared to the frequency of dissections observed in a
diseased wall. Despite a 100% procedural success rate, the
lumen dimensions after balloon angioplasty in the current
study were consistently and significantly smaller than after
stent implantation, with less final MLD and less acute gain.
This observation has already been confirmed by an intravascu-
lar ultrasound study (11) which suggests that the relatively high
residual stenosis is partly as a result of remaining in-stent
neointimal tissue which cannot be totally extruded through the
struts of the stent. The deeper arterial structures surrounding
the stent may also limit the effectiveness of balloon angio-
plasty. We could observe that the reference diameter before
balloon angioplasty for in-stent restenosis was significantly less
than after stent implantation, suggesting that neointimal hy-
perplasia might also affect the initial reference segment.
In our study, angiographic recurrent restenosis rate of the
overall population was very high (54%). Our results suggest
that balloon angioplasty for in-stent restenosis may not be the
ideal treatment, especially for diffuse lesions, because of the
high restenosis rate. Our results differ from those published by
Bauters et al. (16) who reported a 22% angiographic restenosis
rate only. However, the population was different in our two
series with a majority of diffuse lesions in our series (71%) in
comparison to 28% only in the series of Bauters et al. In their
series, diffuse lesions were also associated with a high recurrent
restenosis rate. Similarly, in our series the need for target
revascularization (8%) was very low at follow-up when resten-
osis was focal. The high angiographic restenosis rate presented
in our series, especially in diffuse lesions, could be accounted
for by the nonaggressive approach to repeat balloon angio-
plasty with a mean inflation pressure of 10 atm and a 2.98-mm
balloon diameter. However, in our series, maximal inflation
pressure and maximal balloon diameter were not found to be
predictors of restenosis. Few data are available on alternative
treatments proposed to these patients and not yet evaluated at
long term. Rotational atherectomy and laser angioplasty offer
the potential advantages of debulking the lesion in addition to
the effects of balloon angioplasty, which is systematically
performed after debulking. In the only series (17) reporting the
preliminary results of rotational atherectomy in 100 cases,
procedural success was 100% with no major complications.
Clinical follow-up was obtained for 67% of patients at a mean
of 7 6 2 months: clinical restenosis rate was 27% but no
angiographic follow-up was reported. Laser angioplasty (18,19)
could offer another alternative treatment and has been evalu-
ated in two recent series. Procedural success was achieved in
93% and 98%, respectively. Complications were rare among
the 151 restenosed stents in the LARS Study (18): minor
perforations (1.5%), dissections (8.5%) and non q-wave myo-
cardial infarction (2.3%). In the other study (19), angiographic
follow-up was not performed and subsequent target vessel
revascularization rate was 21%. Directional atherectomy has
not been recommended for in-stent restenosis. Bowerman et
al. (24) reported one case of in-stent restenosis (Gianturco–
Roubin) treated by directional atherectomy. The procedure
was complicated by disruption of the stent which was snared by
the atherectomy cutter. Finally, implantation of a second stent
inside the first one could be another alternative and should
require further investigation. The best therapeutic option
should be assessed with the results of randomized studies
comparing different interventional techniques.
Mechanisms of in-stent restenosis and balloon angioplasty
for in-stent restenosis. The understanding of the mechanisms
of in-stent restenosis and of balloon angioplasty and other
interventional techniques should help in the best choice of
treatment for in-stent restenosis. In an intravascular ultra-
sound study, Hoffman et al. (10) evaluated the mechanisms of
balloon angioplasty for in-stent restenosis and showed that 1)
chronic stent recoil was minimal within Palmaz–Schatz stents,
2) late lumen loss and in-stent restenosis were the result of
neointimal tissue proliferation, 3) neointimal tissue prolifera-
tion was uniformly distributed over the length of the stent
except for a tendency for exaggerated neointimal tissue accu-
mulation at the central articulation of the Palmaz–Schatz stent
and 4) stents appeared to affect the adjacent vessel segments,
causing a combination of arterial remodeling and tissue pro-
liferation. Mechanisms of balloon angioplasty for in-stent
restenosis have also been evaluated by intravascular ultra-
sound. Mehran et al. (11) showed that lumen enlargement
obtained by balloon angioplasty resulted from a combination
of additional stent expansion (accounting for 56% of lumen
enlargement), tissue extrusion out of the stent and neointimal
redistribution within the stent (accounting for 44%). Further-
more, that study showed that angiographic residual stenosis
after balloon angioplasty for in-stent restenosis was relatively
higher in comparison to that observed after stent implantation.
These ultrasound observations are in disagreement with those
of Gordon et al. (7) who, in an angiographic study, concluded
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that lumen enlargement after balloon angioplasty was entirely
due to neointimal tissue compression or extrusion out of the
stent rather than to additional stent expansion. Because the
metallic stainless-steel stent struts are relatively radiolucent
(but intensively echoreflective), intravascular ultrasound ap-
pears more accurate than angiography in providing informa-
tion regarding stent dimensions.
Angiographic pattern of in-stent restenosis and its relation
with recurrent restenosis. In our study, diffuse in-stent resten-
osis pattern was far more common than focal pattern and was
associated with a significantly higher angiographic recurrent
restenosis rate on follow-up in comparison to the focal pattern:
63% vs. 31%. These findings are comparable to those observed
by Sharma et al. (25) who observed diffuse pattern of in-stent
restenosis in 78% of cases. In that same study, clinical recur-
rent restenosis rate was higher when in-stent restenosis was
diffuse vs. focal: 42% vs. 18% (p 5 0.03). These observations
might lead to more aggressive strategies such as laser or
rotational atherectomy for diffuse in-stent restenosis.
Limitations of the study. Several types of stents were
included in our series. This resulted from the prospective
design of the study started in 1995, at the time when several
types of stents were available to accommodate different types
of lesions. However, when subdividing our population accord-
ing to the presence of a coil or a tubular stent, 6-month
recurrent restenosis rate was comparable, in favor of similar
mechanisms for restenosis after balloon angioplasty for in-
stent restenosis. The number of patients is limited but statis-
tically significant to address the problem of restenosis rate
after balloon angioplasty for in-stent restenosis. We are aware
of the superiority of ultrasound over QCA for assessment of
the coronary diameters. However, ultrasound was not available
in this study.
Conclusion. Balloon angioplasty for in-stent restenosis is
associated with excellent immediate results but a high inci-
dence of angiographic recurrent restenosis. The higher recur-
rent restenosis rate observed in diffuse vs. focal lesions suggests
that the treatment of diffuse in-stent restenosis may require
more aggressive debulking strategies. Rotational atherectomy,
laser angioplasty and stenting should be evaluated as alterna-
tives to balloon angioplasty in prospective randomized studies
to determine the best therapeutic option in this indication. The
problem of in-stent restenosis should require careful attention
with the increasing rate of stent implantation all over the world
and the uniform persistence of a restenosis rate of 20% to 30%
after stent implantation.
References
1. Serruys PW, De Jaegere P, Kiemenej F, et al. for the Benestent Study
Group. A comparison of balloon-expandable stent implantation with balloon
angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:
489–95.
2. Fischman DL, Leon MB, Baim DS, et al. for the Stent Restenosis Study
Investigators. A randomized comparison of coronary-stent placement and
balloon angioplasty in the treatment of coronary artery disease. N Engl
J Med 1994;331:496–501.
3. Nakamura S, Colombo A, Gaglione A, et al. Intracoronary ultrasound
observations during stent implantation. Circulation 1994;89:2026–34.
4. Barragan P, Sainsous J, Silvestri M, et al. Ticlopidine and subcutaneous
heparin as an alternative regimen following coronary stenting. Cathet
Cardiovasc Diagn 1995;32:123–8.
5. Morice MC, Zemour G, Benveniste E, et al. Intracoronary stenting without
coumadin: one month results of a French multicenter study. Cathet Cardio-
vasc Diagn 1995;35:1–7.
6. Karillon G, Morice MC, Benveniste E, et al. Intracoronary stent implanta-
tion without ultrasound guidance and with replacement of conventional
anticoagulation by antiplatelet therapy: 30-day clinical outcome of the
French multicenter registry. Circulation 1996;94:1519–28.
7. Gordon P, Gibson M, Cohen D, Carroza J, Kuntz R, Baim D. Mechanisms
of restenosis and redilation within coronary stents—quantitative angio-
graphic assessment. J Am Coll Cardiol 1993;21:1166–74.
8. Baim D, Levine M, Leon M, et al. for the US Palmaz–Schatz investigators.
Management of restenosis within the Palmaz–Schatz coronary stent (the US
multicenter experience). Am J Cardiol 1993;71:364–6.
9. Macander PJ, Roubin GS, Agrawal SK, Cannon AD, Dean LS, Baxley WA.
Balloon angioplasty for treatment of in-stent restenosis: feasibility, safety,
and efficacy. Cathet Cardiovasc Diagn 1994;32:125–31.
10. Hoffmann R, Mintz G, Dussaillant G, et al. Patterns and mechanisms of
in-stent restenosis. A serial intravascular ultrasound study. Circulation
1996;94:1247–54.
11. Mehran R, Mintz G, Popma J, et al. Mechanisms and results of balloon
angioplasty for the treatment of in-stent restenosis. Am J Cardiol 1996;78:
618–22.
12. Topaz O, Vetrovec G. The stenotic stent: mechanisms and revascularization
options. Cathet Cardiovasc Diagn 1996;37:293–9.
13. Houplon P, Juillie`re Y, Selton-Guy C, et al. Absence of risk of conventional
balloon angioplasty for treatment of coronary in-stent restenosis (abstr). Eur
Heart J 1997;18:498.
14. Vahdat B, Bonan R, Paiement P, Bilodeau L, Doucet S, Page E. Manage-
ment of coronary in-stent restenosis by balloon angioplasty (abstr). Eur
Heart J 1997;18:498.
15. Reimers B, Moussa I, Akiyama T, et al. Long-term clinical follow-up after
successful repeat percutaneous intervention for stent-restenosis. J Am Coll
Cardiol 1997;30:186–92.
16. Bauters C, Banos JL, Van Belle E, McFadden E, Lablanche JM, Bertrand
M. Six-month angiographic outcome after successful repeat percutaneous
intervention for in-stent restenosis. Circulation 1998;97:318–21.
17. Sharma S, Duvvuri S, Dangas G, Marmur J, Dailey-Sterling F. Rotational
atherectomy for in-stent restenosis: acute and long-term results of first 100
cases (abstr). Eur Heart J 1997;18:797.
18. Hamm CW, Seabra-Gomes R, Bonnier J, et al. on behalf of the LARS Study
group. Laser angioplasty of within-stent restenosis—results of the LARS
surveillance study (abstr). Eur Heart J 1997;18:497.
19. Mehran R, Mintz G, Satler L, et al. Treatment of in-stent restenosis with
excimer laser coronary angioplasty. Mechanisms and results compared with
PTCA alone. Circulation 1997;96:2183–9.
20. Campeau L. Grading of angina pectoris (letter). Circulation 1976;54:522.
21. Guidelines for Percutaneous Transluminal Coronary Angioplasty. A report
of the American College of Cardiology/American Heart Association. Task
Force on assessment of diagnostic and therapeutic cardiovascular proce-
dures (Subcommittee on Percutaneous Transluminal Coronary Angio-
plasty). J Am Coll Cardiol 1988;12:529–45.
22. Huber SM, Mooney JD, Madison J, Mooney MR. Use of a morphologic
classification to predict clinical outcome after dissection from coronary
angioplasty. Am J Cardiol 1991;68:467–71.
23. Detre K, Holubkov R, Kelsey S. Percutaneous transluminal coronary
angioplasty in 1985–1986 and 1977–1981: the National Heart, Lung and
Blood Institute Registry. N Engl J Med 1988;318:265–70.
24. Bowerman R, Pikerton C, Kirk B, Waller B. Disruption of a coronary stent
during atherectomy for restenosis. Cathet Cardiovasc Diagn 1991;24:248–51.
25. Sharma SK, Karakala V, Dangas G, Duvvuri S, Ambrose J. Angiographic
patterns of in-stent restenosis after Palmaz–Schatz stent implantation and
implication on subsequent outcome (abstr). Eur Heart J 1997;18:451.
984 ELTCHANINOFF ET AL. JACC Vol. 32, No. 4
BALLOON ANGIOPLASTY FOR IN-STENT RESTENOSIS October 1998:980–4
